Application of fluorescence
Bladder transitional-cell carcinoma
Detection
Fluorescence in situ hybridization
Grade
Stage
Journal
Asian journal of urology
ISSN: 2214-3882
Titre abrégé: Asian J Urol
Pays: Singapore
ID NLM: 101699720
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
03
2017
revised:
04
09
2017
accepted:
27
09
2017
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
ppublish
Résumé
To evaluate the diagnostic value of fluorescence We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) values were calculated for both the FISH and urine cytology tests. A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population. A total of 4807 patients with hematuria were prospectively, randomly enrolled for the simultaneous analysis of urine cytology, FISH testing, and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen. Overall, the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%, while that of cytology was 33.4% ( FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages. Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors.
Identifiants
pubmed: 30775255
doi: 10.1016/j.ajur.2018.06.001
pii: S2214-3882(18)30042-0
pmc: PMC6363605
doi:
Types de publication
Journal Article
Langues
eng
Pagination
114-121Références
Cancer. 1999 Jun 25;87(3):118-28
pubmed: 10385442
Cancer Res. 2001 Nov 15;61(22):8241-6
pubmed: 11719456
J Urol. 2002 Nov;168(5):1950-4
pubmed: 12394683
Histol Histopathol. 2003 Jan;18(1):259-74
pubmed: 12507305
Urology. 2003 Jan;61(1):109-18; discussion 118
pubmed: 12559279
J Urol. 2003 Jun;169(6):1975-82
pubmed: 12771702
J Urol. 2003 Jun;169(6):2101-5
pubmed: 12771727
J Cell Biochem Suppl. 1992;16I:76-9
pubmed: 1305693
Eur Urol. 2005 Jun;47(6):736-48
pubmed: 15925067
Urology. 2005 Dec;66(6 Suppl 1):35-63
pubmed: 16399415
Cancer. 2007 Dec 25;111(6):517-24
pubmed: 17963263
Eur Urol. 2008 May;53(5):909-16
pubmed: 18162285
Urol Oncol. 2008 May-Jun;26(3):246-9
pubmed: 18452813
J Mol Diagn. 2009 Mar;11(2):148-54
pubmed: 19179455
Can J Urol. 2010 Apr;17(2):5077-81
pubmed: 20398445
Urol Oncol. 2012 May-Jun;30(3):273-7
pubmed: 20451422
Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Aug 18;42(4):381-5
pubmed: 20721247
Anticancer Res. 2010 Nov;30(11):4761-5
pubmed: 21115937
Urology. 2011 Apr;77(4):855-9
pubmed: 21296388
Neoplasma. 2012;59(4):355-60
pubmed: 22489689
Urol Oncol. 2013 Nov;31(8):1656-62
pubmed: 22621963
J Urol. 2013 Oct;190(4):1181-6
pubmed: 23583531
BJU Int. 2014 Apr;113(4):662-7
pubmed: 23890221
BMC Urol. 2016 Jun 13;16(1):30
pubmed: 27296150
Can J Urol. 2017 Feb;24(1):8620-8626
pubmed: 28263126
Oncol Lett. 2017 May;13(5):3928-3934
pubmed: 28529600
Scand J Urol Nephrol. 1987;21(3):185-95
pubmed: 3433019
Cancer. 1994 Sep 1;74(5):1621-6
pubmed: 8062194
Eur J Cancer. 1995 Oct;31A(11):1840-6
pubmed: 8541110
Urol Res. 1997;25 Suppl 1:S37-43
pubmed: 9079755
CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84
pubmed: 9742894